Lipid Profile in Leukemia and Non-Hodgkin Lymphoma Patients

The high rates of glucose uptake, fueling glycolysis, are now used clinically to identify cancer cells. Therefore, the oncogenes, variable hypoxia levels and the utilization of different carbon sources affect tumor evolution. At the time glucose is regarded as a main source of carbon and energy, there are also lipids. In latest years, researchers were paying attention to studying the role of lipids in different types of malignancies. Decreased blood lipid levels have been observed in various forms of cancer including pancreatic, lung, ovarian and colonic cancers. The aim of current study was to investigate the lipid profile of individuals with hematological malignancies and its relationship to disease activity. Hematological malignancies groups that involved in this study were (Acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia and chronic myeloid leukemia).

Samples (serum and bone marrow) were obtained from each group to investigate lipid profile (total cholesterol, triglycerides, low-density lipoprotein and very-low lipoprotein). In Acute myeloid leukemia, samples were collected from patients before and after treatment.

The results showed that triglycerides and very low-density lipoproteins were significantly increased (P<0.05) when compared to control group in both samples; whereas in acute lymphoid leukemia, they were significantly decreased (P<0.05). Serum and bone marrow lipid profiles in chronic myeloid leukemia and non-Hodgkin lymphoma were significantly high.

Based on the finding of this study on Iraq patients, it looked like that lipid profile assessment can be used as a beneficial prognostic factor in leukemia and non-Hodgkin patients. Also, it can be a simple, economical and fast method for following up patients’ responses to chemotherapy